Anivive Lifesciences featured in LA Business Journal
On May 29, the Los Angeles Business Journal highlighted Anivive Lifesciences's work to launch an anti-fungal vaccine — the first ever — targeting Valley fever, a disease that threatens up to 30 million dogs. Anivive also expects to potentially use the product in humans, who are affected by the same disease.
Reporter Zane Hill wrote that the company recently kicked off a fundraising campaign targeting $50 million in investments. Reaching this figure would double the company’s total fundraising, after its founders and board members internally pooled together its initial funding.
Dylan Balsz, the company's CEO, said that Anivive Lifesciences had its first net profit last year and is gearing up to put its new vaccine, for Valley fever, onto the market.
“We were able to be profitable last year," said Balsz in the story. "This year, we’re investing heavily in this launch, so we expect to return to profitability within the next 12 months. We didn’t expect this economic environment, but it’s given us the runway to fund this launch.”
Hill said in his story that eight different university teams are involved in research and nearly $20 million in grants have allowed Anivive to contract with other researchers.
Anivive's investors include current and former NFL stars Jamal Adams, John Elway and Rob Gronkowski, as well as Glenn Stearns of “Undercover Billionaire” fame and Gavin Herbert Sr., the founder of Allergan.
In 2019, there were 20,003 cases of Valley fever reported to the Centers for Disease Control and Prevention (CDC). Most of these cases were in people who live in Arizona or California. Rates of Valley fever are typically highest among people aged 60 and older. Learn more about Valley fever on the CDC's website.
Read more in the LA Business Journal's story.
Read the interview with Balsz published in March 2023: https://www.veterinary33.com/articoli/companies/1353/anivive-lifesciences-tackles-unmet-animal-health-needs.html
Comments
Related Articles
More news
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment